Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials

Acta Cirurgica Brasileira

Volumn 23, Issue 6, 2008, Pages 520-530

  Lustosa, Suzana Angélica Silva ^a   Saconato, Humberto ^b   Atallah, Álvaro Nagib ^b   Lopes Filho, Gaspar De Jesus ^b   Matos, Delcio ^b,c  

^a UNIFOA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Clinical trial; Lymph node excision; Meta analysis; Prognosis; Stomach neoplasms

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; GASTRECTOMY; HOSPITALIZATION; HUMAN; LYMPHADENECTOMY; MORBIDITY; STOMACH CANCER;

GASTRECTOMY; HOSPITAL MORTALITY; HUMANS; LYMPH NODE EXCISION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 57349139979     PISSN: 01028650     EISSN: 16782674     Source Type: Journal    
DOI: 10.1590/S0102-86502008000600009     Document Type: Article

References (31)

1. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery and its limits for radicality. World J Surg.1987;11:418-26.
2. Nakajima T, Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology. 1989;36:79-85.
3. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522-30.
4. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908-14.
5. Robertson CS, Chung SCS, Woods SDS, Griffin SM, Raimes SA, Lau JTF, Li AKC. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg. 1994;220:175-82.
6. McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg. 2005;92:5-13.
7. Hartgrink HH, Putter H, Bonenkamp JJ, Klein Kranenberg E, Songun I, Welvaart K, van Krieken JHJM, Meijer S, Plukker JTM, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJB, Taat CW, de Graaf PW, von Meyfenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069-77.
8. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75:110-2.
9. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. QUORUM Group. Improving the quality of reports of meta-analyses of randomized controlled trials; the QUORUM statement. Lancet. 1999;354:1896-900.
10. Schulz K. Subverting randomization in controlled trials. J Am Med Assoc. 1995;274:1456-8.
11. Mahid SS, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic review and meta-analysis for the surgeon scientist. Br J Surg. 2006;93:1315-24.
12. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JTM, van Elk P, Obertop H, Gouma DJ, Taat CW, van Lanschot J, Meyer S, de Graaf PW, von Meyenfeldt MF, Tilanus H, van de Velde CJH. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745-8.
13. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. Lancet. 1996;347:995-9.
14. Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol. 1998;16:1490-3.
15. Wu CW, Hsiung CA, Lo SS, Hscih MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg. 2004:91:283-7.
16. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial. EJSO. 2004;30:303-8.
17. Wu CW, Hsiun CA, Lo SS, Mao-Shin H, Jen-Hao C, Fen-Yau L, Wing-Lui L, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309-15.
18. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg. 2007;193:10-5.
19. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy - Japan Clinical Oncology Group Study 9501. J Clin Oncol. 2004;14:2767-72.
20. Danielson H, Kokkola A, Kiviluoto T, Siren J, Louhimo J, Kivilaakso E, Puolakkainen P. Clinical outcome after D1 vs D2-3 gastrectomy of gastric cancer. Scand J Surg. 2007;96:35-40.
21. Kunisaki C, Akyiama H, Nomura M, Matsuda G, Otsuka Y, Ono H, Nagahori Y, Hosoi H, Takahashi M, Kito F, Shimada H. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann Surg Oncol. 2006;13:659-67.
22. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, Kamata S, Yamamoto H, Kim BS, Matsuki N, Sawa T, Noh SH. Operative morbidity alter D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology. 2006;53:389-94.
23. Marreli D, Pedrazzani C, Neri A, Corso G, DeStefano A, Pinto E, Roviello F. Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer: analysis of potential risk factors. Ann Surg Oncol. 2007;14:25-33.
24. Tsujinaka T, Sasako M, Yamamoto S, Sano T, Kurokawa Y, Nashimoto A, Kurita A, Katai H, Shimizu T, Furukawa H, Inoue S, Hiratsuka M, Kinoshita T, Arai K, Yamamura Y. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol. 2007;14:355-61.
25. Gunderson L. Radiation therapy: results and future possibilities. Clin Gastroenterol. 1976;5:743-76.
26. Bunt AMG, Hermans J, Smit VTHM, van de Velde CJH, Fleuren GJ, Bruijn JA. Surgical/Pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and western countries. J Clin Oncol. 1995;13:19-25.
27. Yoshikawa T, Sasako M, Sano T, Nashimoto A, Kurita A, Tsujinaka T, Tanigawa N, Yamamoto S. Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from the results of a prospective randomized trial. Br J Surg. 2006;93:1526-9.
28. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Stage migration influences on stage specific survival comparison between D1 and D3 gastric cancer surgeries. EJSO. 2005;31:153-7.
29. Wang XF, Sun YH, Liang DJ. Clinical values of extended lymph node dissection for gastric cancer: a meta-analysis for D1 versus D2 gastrectomy. Zhongua Wei Chang Wai Ke Za Zhi. 2007;10:425-30.
30. Sasako M, Sano T, Yamamoto S. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
31. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg. 2007;94:263-4.